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ABSTRACT
Background: Helicobacter pylori remains a global health
hazard, and vaccination would be ideal for its control.
Natural infection appears not to induce protective
immunity. Thus, the feasibility of a vaccine for humans is
doubtful.
Methods: In two prospective, randomised, double-blind,
controlled studies (Paul Ehrlich Institute application nos
0802/02 and 1097/01), live vaccines against H pylori
were tested in human volunteers seronegative for, and
without evidence of, active H pylori infection. Volunteers
(n = 58) were immunised orally with Salmonella enterica
serovar Typhi Ty21a expressing H pylori urease or
HP0231, or solely with Ty21a, and then challenged with
26105 cagPAI2 H pylori. Adverse events, infection,
humoral, cellular and mucosal immune response were
monitored. Gastric biopsies were taken before and after
vaccination, and postchallenge. Infection was terminated
with antibiotics.
Results: Vaccines were well tolerated. Challenge
infection induced transient, mild to moderate dyspeptic
symptoms, and histological and transcriptional changes in
the mucosa known from chronic infection. Vaccines did
not show satisfactory protection. However, 13 of 58
volunteers, 8 vaccinees and 5 controls, became breath
test negative and either cleared H pylori (5/13) completely
or reduced the H pylori burden (8/13). H pylori-specific T
helper cells were detected in 9 of these 13 (69%), but
only in 6 of 45 (13%) breath test-positive volunteers
(p = 0.0002; Fisher exact test). T cells were either
vaccine induced or pre-existing, depending on the
volunteer.
Conclusion: Challenge infection offers a controlled model
for vaccine testing. Importantly, it revealed evidence for T
cell-mediated immunity against H pylori infection in
humans.
Half of the world’s population is infected with
Helicobacter pylori. Infection causes gastritis, peptic
ulcer and gastric cancer.1 Although infection may
be beneficial in some cases,2 3 its pathological
consequences outweigh currently projected bene-
ficial roles. Antibiotic resistance and compliance
problems significantly reduce treatment efficacy.4
In developing countries, re-infection is common,
and current treatment options are inadequate for
control. An effective vaccine, however, could
prevent re-infection and offer cost-effective infec-
tion management.
To date, immunity against H pylori has only been
obtained in animal models5 6 where protection
depends, at least in part, on induction of T helper
cells.7 In contrast, natural infection in humans
appears specifically to inhibit T cell responses via
induction of regulatory T cells8 9 and direct inhibi-
tion of T cell activation.10–12 Although various
vaccines have been tested in clinical trials (for
reviews see Ruggiero et al.13 and Aebischer et al14), it
remains unclear whether immunity against H pylori
exists in humans and whether vaccination is feasible.
We tested live vaccines based on recombinant
Salmonella Ty21a, the licensed typhoid fever vaccine,
in volunteers subsequently challenged with H
pylori.15 Although the vaccines were not satisfactory,
the studies revealed clearly that T cell reactivity
against H pylori antigens correlated with clearance or
significant reduction of H pylori burden.
METHODS
Vaccine strain construction and challenge H pylori
strain
Construction of recombinant Ty21a vaccines
expressing H pylori urease A and B subunits
(Ty21a(pUreA/B)) or HP0231 (Ty21a(pHP0231),
respectively, is described in the supplementary
material and in Bumann et al.16 Frozen Salmonella
of known 1010 colony-forming units (cfu) were
thawed and resuspended in 30 ml of phosphate-
buffered saline (PBS) for oral vaccination.
The H pylori challenge strain has been
described.15 Volunteers were infected with 26105
freshly grown bacteria, resuspended in 30 ml of
instant soup (Maggi) for infection. Cfus were
confirmed by plating.
Study design
Two prospective, randomised, double-blind, con-
trolled studies were designed (for diagrams see
supplementary figs 2 and 3) as a combination of
two consecutive protocols: vaccination and chal-
lenge infection. Infection was monitored over
predefined periods before the application of anti-
biotic therapy to terminate infection, independent of
vaccine effect. The first study was planned as a pilot
trial to assess primarily the safety of the approach.
The second study was planned based on the
outcome of the first trial to assess protective effects.
Helicobacter pylori
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Participants
The pilot study was conducted in 2003–4. Twenty subjects
were enrolled at the Medical Clinic I, Charite´ Campus Benjamin
Franklin, Berlin. Eligible subjects were male, aged between 20
and 50 years, healthy with normal routine blood and chemical
laboratory parameters, negative for H pylori infection by
[13C]urea breath test (UBT), serology and stool antigen test.
Exclusion criteria were abnormal upper gastrointestinal tract
endoscopy including analysis of biopsies, history of typhoid
fever vaccination, history of disease of the biliary or gastro-
intestinal tract, recent drug prescriptions, allergies to antibio-
tics, a diet rich in sour or fermented food, cases of gastric cancer
in close relatives and regular contact with children younger than
12 years.
The second study was conducted between December 2004
and April 2006. Of 133 subjects assessed and screened as above,
47 volunteers were enrolled at the Medical Clinic I, Charite´,
Campus Benjamin Franklin, Berlin.
Ethics
The study protocols were developed adhering to the Declaration
of Helsinki, reviewed and approved by the ethical review board
of the Charite´, Berlin, and the studies were registered with the
responsible German federal authority, the Paul Ehrlich Institute
(applications nos 0802/02 and 1097/01).
All volunteers were informed about the study protocol,
potential risks and adverse reactions to vaccination and
challenge infection before giving written consent.
Interventions
In the first study, there were three treatment arms for
vaccination: volunteers were given three doses of 1010 bacteria
orally on day 0, 2 and 4 of the Ty21a control (n = 4), or
Ty21a(pUreA/B) vaccines containing either expression plasmid
pDB2 (n = 8) or pDB3 (n = 8). On day 5, 7, 10 and 28
postvaccination, blood was taken for serology and analysis of
responses in peripheral blood monocytic cells (PBMCs). Four
weeks after vaccination, gastroscopy with biopsy was repeated.
Volunteers were interviewed repeatedly to record untoward
events.
Because serious adverse events due to challenge could not be
excluded, the code was broken in week 6 after vaccination to
select one volunteer per treatment arm (volunteer nos 2, 8 and
16) based on a similar response to the Ty21a carrier. Volunteers
remained blinded and were challenged with H pylori on day 42
postvaccination and again alerted to report adverse reactions.
Infection was monitored by UBT on day 3, 7, 14 and 38 post-
challenge and weekly thereafter. Serum was obtained on day 7
and 14, and PBMCs were obtained on day 38 postchallenge.
Endoscopy was repeated in week 6 after challenge, and biopsies
were taken for H pylori culture, histology, determination of local
cytokine secretion and mRNA preparation. Thereafter, H pylori
was eradicated by triple therapy for 7 days combining
amoxicillin, clarithromycin and pantoprazol (ACP; ZacPac).
Eradication was confirmed by UBT on days 68 and 132 after
challenge. As gastritis was similar in all three subjects and no
severe untoward events were noted, the remaining 17 volun-
teers were contacted. One could not be contacted and six
volunteers declined. Ten volunteers were enrolled for challenge
infection which took place 5 months after vaccination.
Monitoring and sample collection were performed at the same
time intervals postchallenge as before. Therapy was initiated in
week 8 instead of week 6 postchallenge.
In the second study volunteers were allocated to a first arm
for vaccination with control Ty21a (n = 22). Volunteers
allocated to a second arm (n = 12) were given the recombinant
Ty21a(pUreA/B) holding plasmid pDB2 used in the first study.
Volunteers in the third arm (n = 13) were given a novel vaccine
strain expressing antigen HP0231, Ty21a(pHP0231). Given
capacity constraints, the rationale for introducing the latter
and omitting one Ty21a(pUreA/B) vaccine used in the first
study was as follows: no differences in immunogenicity were
detected between Ty21a(pUreA/B) vaccines; hence only one
was selected for further testing. Ty21a(pHP0231) was included
because corresponding vaccines were equally efficient in
protecting mice compared with the gold standards H pylori
lysate and S typhimurium (pureA/B)22 (TA, DB unpublished).
Furthermore, the North American schedule of four vaccine
doses given every other day was adopted to maximise responder
numbers.
Of the 47 vaccinated volunteers, 45 were infected with H
pylori on day 42 as described above. Two withdrew from the
study. The observation period after challenge infection was
extended to 3 months and instead of blood collection and a
gastroscopy on day 28 (postvaccination), blood samples were
collected and gastroscopy performed after week 6 and 10
postinfection. Infection was terminated by antibiotic therapy as
described above, and success was monitored 1 and 3 months
later.
Objectives
The primary objectives were to assess safety, immunogenicity
and potential protective effect of prophylactic vaccination with
live, recombinant Salmonella Ty21a vaccines in human volun-
teers experimentally challenged with H pylori. The secondary
objective was to test whether protection, if it existed, was
correlated with a particular type of immune response.
Outcomes
The primary end point was protection from a H pylori
challenge—that is, negative testing in four diagnostic tests for
active H pylori infection. The four tests were UBT, rapid urease
test (RUT) on biopsies, H pylori detection by histochemistry and
culture from biopsies.
Secondary outcomes were histological changes and T and B
cell response patterns, assessed by cytokine and antibody
production, respectively. A secondary end point for evidence
of protection was re-defined for post hoc analyses and consisted
of repeatedly negative UBT and negativity in at least one of the
three remaining diagnostic tests.
Sample size
The first study was designed as a pilot study primarily to assess
the safety of the vaccination cum challenge infection model.
Sample size was determined based on previous studies with the
vaccines used, when 33–56% of volunteers generated a specific T
cell response. Thus, groups of 8 volunteers were immunised
with the recombinant vaccines and 4 volunteers were given the
control Ty21a. It was expected that 30–50% of volunteers
would generate a urease-specific T cell response and, if this were
correlated with protection, the trend should be detectable.
A minimal group size of 20 in the vaccine (cumulated vaccine
groups) and 20 in the control groups for the second study was
determined using the PS program (http://biostat.mc.vanderbilt.
edu/twiki/bin/view/Main/PowerSampleSize) based on the out-
come of the first study—that is, indications of clearing response
Helicobacter pylori
1066 Gut 2008;57:1065–1072. doi:10.1136/gut.2007.145839
group.bmj.com on November 26, 2017 - Published by http://gut.bmj.com/Downloaded from 
in 5 of 9 vaccinees (55%) and assuming a frequency of 10% of
volunteers in the control groups with a clearing response. The
hypothesis that no difference between vaccinees and controls
existed was to be tested with a power of 0.8 at a significance
level of 0.05 by two-sided Fisher exact test using a dichotomous
outcome (protected/non-protected).
Randomisation
Volunteers were assigned a continuous number upon screening
that served as a volunteer ID throughout the studies. To
generate a random sequence of vaccine allocation, ID numbers
of enrolled volunteers were drawn blindly from a hat by a
collaborator not involved in screening or enrolment. The
allocation key was concealed and not disclosed to personnel
involved in administering the vaccines.
On the days of vaccination, volunteers were given vaccines in
ascending order according to their ID, being administered
vaccine doses labelled with their ID by the person who
generated the allocation key.
The study physician and personnel involved in direct contact
with volunteers were blinded and ignorant of the allocation
sequence of treatment arms.
Analytical procedures
Histological analyses were performed as described17 by a single
pathologist (MS) blinded to treatment keys.
Antibody-secreting cells (ASCs) and specific T cells were
monitored. Cryopreserved PBMCs from the same volunteer
collected at different times were thawed and analysed simulta-
neously. ASCs were enumerated by ELISPOT.18 T cells were
analysed by multichromatic cytofluorimetry19 20 after in vitro
stimulation of PBMCs with a Salmonella lysate (anticarrier
response), and with recombinant urease A (first study) or
overlapping peptide pools (15mer peptides with 12mer overlaps)
representing urease A/B or HP0231 (see supplementary informa-
tion). Cells cultured in medium or stimulated with Staphylococcal
enterotoxin B served as negative and positive controls, respec-
tively. Responses were compared in PBMCs prepared before
vaccination, at day 5 postvaccination, and 6 weeks and 3 months
after challenge infection, totalling .1000 samples.
Local cytokines were determined in biopsy culture super-
natants21 by cytometric bead array (CBA system, BD; see
supplementary information).
Transcriptional profiling was performed analysing total RNA
from antrum biopsies on a custom-made microarray (see
supplementary information).
Statistical analyses
Quantitative parameters of post hoc analyses are presented as
medians and range when data sets were not all normally
distributed, and groups compared by two-sided, non-parametric
tests using Graphpad Prism4.
Significant T cell responses were determined based on a
threshold of mean prevaccination level +3 SD after testing that
prevaccination numbers of memory CD45RA2, a4b7 integrin+
CD4+ cells expressing interferon c (IFNc) (first study) or CD40L
and interleukin 2 (IL2) (second study) were normally distributed
(identified outliers in study 2 were excluded from analysis).
Volunteers were classified into CD4 T cell responders and non-
responders and, based on UBT results, as UBT+ or UBT2. As a
null hypothesis, the independence of UBT results and CD4 T
cell responses was evaluated by two-sided Fisher exact test.
Differences in T cell response quality between UBT+ and
UBT2 groups were analysed using Statistica 6 software by
factorial analysis of data on 14 different T cell subpopulations
(eg, CD4+ or CD8+, CD40L+ or CD40L 2, IFNc+ or IFNc2 cells
analysed at four time points and restimulated in vitro with
different antigens). The first factor captured .70% of the
variation in either group and was composed of different T cell
subpopulations.
RESULTS
Adverse effects of vaccination and challenge infection
Vaccines were well tolerated, with minor adverse effects such as
gastrointestinal nausea (2/20), mild diarrhoea (2/20) and head-
aches (5/20) reported on single days over a 28 day period (see
supplementary table 1). Infection with H pylori caused
dyspeptic symptoms such as nausea and abdominal pain that
started around day 3 after challenge, but were transient and
resolved after 2 weeks in the great majority of volunteers
(supplementary fig 2). In each treatment group, one volunteer
developed transient grade 3 adverse effects after challenge, with
nausea, vomiting, strong abdominal pain and diarrhoea. One
volunteer developed a small ventricular ulcer that had com-
pletely resolved after 2 weeks of proton pump inhibitor therapy.
No serious adverse events were observed, and neither vaccina-
tion nor challenge interfered significantly with the volunteers’
daily activities.
Course of infection in vaccinated and control-treated volunteers
Infection was monitored by four tests: continuously by UBT,
and by RUT, silver staining and culture of biopsy material
obtained after 6 weeks and in the third month of infection
(second study only). Test results were classified as positive or
negative to compute an overall H pylori score (0 = all tests
negative, 4 = all positive). Volunteers tested negative in all tests
at baseline. Protection as a primary end point was defined as a H
pylori score of 0 in week 6.
In the first study, which was designed as a pilot trial, 13 of 20
volunteers vaccinated were infected with H pylori (4 controls
and 9 vaccinees) and all developed a positive UBT by day 7 after
challenge, indicating reliable and successful infection (fig 1A).
Five individuals developed repeatedly negative UBT after week 3
postchallenge (fig 1B). In week 6, three of nine vaccinees (33%)
but none of the four control volunteers had a score of 0 (table 1),
suggesting a protective vaccine effect. Therefore, protection was
tested in a second study.
The second study followed the same design principle to
evaluate the live vaccines Ty21a(pureA/B) used in the first trial
and a novel vaccine, Ty21a(pHP0231) expressing the H pylori
antigen HP0231 that was found in a mouse model to be
protective.22 Disappointingly, there was no significant difference
between vaccine and control groups with regard to the primary
end point, H pylori infection (table 2).
However, 6 weeks after challenge, the H pylori score was 0 in
two volunteers, and six others were negative in two of four tests.
Similarly to the first study, after initially testing positive, these
volunteers repeatedly tested negative in UBT after week 3
(fig 1C,D). Four volunteers with a H pylori score of ,2 were
observed in the control group and four in the recombinant
vaccine-treated groups. Of note, clearance after successful
infection has not been observed in 18 volunteers in previous
studies designed to define the infectious dose of the present
challenge strain.15
Helicobacter pylori
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Histological response to vaccination and challenge
Antrum and corpus mucosa were evaluated for the grade of
leucocytic infiltrations, infiltrate activity, grade of regenerative
epithelial replacement and mucus depletion. These four para-
meters were individually scored on a scale of 0–3 and scores
were cumulated to reflect overall histological changes due to
vaccination and infection.
Vaccination alone had no detectable effect on the gastric
mucosa (cf. supplementary table 2) and did not induce
significant changes in local cytokine production (not shown).
In contrast, all volunteers developed typical H. pylori
gastritis15 6 weeks after challenge. Importantly, vaccination
did not exacerbate inflammation (cf. supplementary tables 2
and 3 for first and second study, respectively). Transcriptional
profiling of biopsies taken in week 6 showed that infection
increased mucosal chemokine and cytokine mRNA abun-
dance (see supplementary table 4 for a list of all affected
mRNAs). In agreement with this, we measured higher levels
of IL1-b, IL2, IL4, IL5, IL6, IL10, IL12, IFNc or tumour
necrosis factor a (TNFa) protein in supernatants of cultured
biopsies from that time point (see supplementary fig 5), yet
detected no differences in these between treatment groups.
Regulatory T cells expressing the FoxP3 transcription factor23
were also enumerated in the mucosa, as these cells are
thought to contribute to chronic infection.8 9 FoxP3+ cells
were rare in uninfected stomach mucosa and the 6-week
infected organs, but numbers increased 3 months after
infection (supplementary fig 6).
Figure 1 Course of H pylori infection in
vaccinated volunteers. A breath test was
used to monitor the course of infection in
experimentally challenged volunteers over
time. (A, B) [13C]urea breath test (UBT)
results of 4 Ty21a control (%) and 9
Ty21a(pUreA/B) (&) vaccinated
volunteers in the first study. (C, D) UBT
results of control (%), Ty21a(pUreA/B)
(&) and Ty21a(pHP0231) (N) vaccinated
volunteers in the second study. Values
correspond to mean (SD) UBT results of
vaccine groups repeatedly tested at the
indicated times postchallenge infection.
(B) and (D) UBT results over time of
individual volunteers in study 1 and 2,
respectively, who although initially testing
positive after challenge, tested repeatedly
negative (threshold UBT values DoB
,1.5; stippled line) after week 3. ‘Ch.’
and arrow denote time of challenge
infection, ‘Treatment’ and arrow mark the
start time of antibiotic eradication.
DoB, delta over baseline.
Table 1 Effects of vaccination on H pylori infection (first study)
Vaccine Ty21a control Ty21a(pUreA/B)
Volunteer 2 6 7 12 4 8* 10 13* 15 5* 16 18 20
Test{
H pylori culture – – + + + – + – + – – – –
RUT + – + + + – + – + – – – +
UBT + – + + + + + + + – – – –
H pylori
histology
+ + – + + + + + + – – – –
Score{ 3 1 3 4 4 2 4 2 4 0 0 0 1
*Volunteers receiving the Ty21a(pureA/B) vaccine containing plasmid pDB3.
{H pylori colonisation was determined by culture of biopsies, RUT on biopsies and Warthin Starry staining of biopsy sections in
addition to UBT.
{Sum of positive tests at 6 weeks and/or 3 months postchallenge; clearing volunteers with a score (2 are marked in bold.
RUT, rapid urease test; UBT, [13C]urea breath test.
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Immunological responses
Salmonella vaccination can induce broad, mucosa-targeted B
and T cell responses.24 25 B cell responses were analysed at day 7
after the first vaccination when ASC numbers against the
carrier peak in circulation. Vaccination induced significant
numbers of anti-Salmonella-specific ASCs in 25% of volunteers
in the first study and, depending on the group, in 45–75% in
the second study (supplementary table 5). B cell responses to
the carrier were in the range expected for these Ty21a vaccines
but, as reported,16 18 vaccine antigen-specific ASCs were below
detection.
In contrast, not only Salmonella-carrier but also vaccine
antigen-specific—that is, cytokine-producing, eg IFNc+ T cells
were detectable by multicolour flow cytometry in in vitro
stimulated PBMCs (supplementary table 6). After vaccination
(day 5), carrier-specific CD4+ T cells were detected in 20–25% of
volunteers in both studies. Urease-specific CD4+ T cells were
observed in 25% of Ty21a(pureA/B) in study 1 and in 8% of the
respective vaccinees in study 2. HP0231-specific T cells were
detectable in 33% of Ty21a(pHP0231)-vaccinated individuals.
Antigen-specific CD8+ T cells were not observed (not shown).
After challenge, we recorded urease-specific T cells in 56% of
Ty21a(pureA/B) vaccinees (up from 25%) in the first study and
25% (up from 8%) in the second study. In the Ty21a(pHP0231)-
treated group, an increase was only observed 3 months after
infection (to 42% from 33%).
Unexpectedly, T cells reactive to carrier antigens were
detected in five, and against vaccine antigens in six volunteers
already before vaccination. In four of the latter, these reactions
were against both vaccine antigens, possibly indicating previous
exposure to H pylori.
Post hoc analyses
Comparative analysis of secondary outcomes in UBT+ and UBT2
volunteers
While 43 of 58 (74%) volunteers in the two studies remained
UBT positive until infections were eradicated, 13 (22%) tested
repeatedly negative and were negative in at least one additional
diagnostic test. As this may have indicated active reduction of H
pylori burden, a negative UBT and a H pylori score of ,2 was
used to classify volunteers into UBT2 and UBT+ groups for a
post hoc analysis.
We first tested whether H pylori burdens were significantly
lower in the so-defined UBT2 volunteer group. Indeed H pylori
was reduced to ,100 cfu/biopsy or undetectable, and thus was
significantly different from the ,104 cfu/biopsy found in UBT+
volunteers (fig 2; p,0.0001; Mann–Whitney U test).
We next compared histological parameters (supplementray
tables 2 and 3) between UBT2 and UBT+ volunteers. Six weeks
postchallenge, inflammation of the antrum and corpus showed
no significant difference in extent or localisation between these
groups. However, 3 months postchallenge, UBT+ volunteers had
established an antrum-predominant inflammation pattern, a
change not observed in the other volunteers (fig 3).
In animal models, reduction of bacterial burden requires
specific T cells, and histological correlates such as altered
inflammation have been described.26 As vaccine antigen-specific,
circulating T cells were determined here (supplementary table
6), we tested whether these were correlated with reduced H
pylori scores. Four of five volunteers (80%) in the first study and
five of eight volunteers (62%) in the second study in the UBT2
group showed significant H pylori-specific T cell responses
6 weeks postinfection (fig 4). In contrast, H pylori-specific T
cells in PBMCs were detectable in only two of eight (25%; first
study) and four of 37 (11%; second study) UBT+ volunteers. The
negative correlation between T cell response and UBT positivity
was significant in the second study, and was highly significant
in the cumulated setting (Fisher exact test: first study p = 0.103,
second study p = 0.004; if cumulated, p = 0.0002).
DISCUSSION
Despite promise in preclinical models, the feasibility of
vaccination against H pylori in humans remains unclear.5 In
other cases of human-specific pathogens, experimental infection
of volunteers for the development of vaccines has provided
Figure 2 H pylori burdens are significantly reduced in [13C]urea breath
test (UBT)-negative volunteers. Biopsies obtained 6 weeks (second
gastroscopy; 2nd) and 3 months (third gastroscopy; 3rd) after infection
from the antrum and corpus were processed to determine H pylori
colony-forming units (cfu). Data are represented by box and whisker
plots which indicate median, range and 25th–75th centiles of the log10
transform of cfu counted per biopsy of the UBT2 (shaded box) and UBT+
(open box) group of volunteers. Differences in colonisation were highly
significant (p,0.0001 in all cases; two sided Mann–Whitney test).
Figure 3 Development of antrum-predominant gastritis in [13C]urea
breath test (UBT)-positive volunteers 3 months after challenge infection.
Gastritis grade, activity, mucus depletion and regenerative changes were
scored on a scale of 0–3. Data are represented in box and whisker plots
which indicate median, range and 25th–75th centiles of the cumulative
histological scores observed in UBT2 (shaded box) and UBT+ (open box)
volunteers (cf. supplememtary tables 3 and 4). Histological scores of
corpus gastritis were significantly different between the groups
(*p,0.05; two-sided Mann–Whitney test).
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crucial insight.27–33 Here, we chose this approach to clarify the
feasibility of vaccinating humans against H pylori. Like others,34
we critically evaluated this approach, and alternatives, such as
therapeutic vaccination or field trials, were considered but
would have had major drawbacks. For example, boosting non-
protective, even pathogenic responses35 36 in patients who may
harbour treatment-resistant H pylori could not be excluded. The
use of a defined challenge strain appeared to be advantageous in
view of the extreme genetic variance of H pylori in patients.
Safety was of cardinal concern, and three vaccinated
volunteers were challenged first to monitor clinical symptoms
and tissue response. These were no different from those
previously reported for non-vaccinated volunteers.15
Histological changes and the transcriptional profile recapitu-
lated essential features of H pylori infection as known from
patients,17 37 and immediate resolution of inflammation even in
clearing volunteers was not expected since gastritis also
improves relatively slowly after antibiotic eradication.15 38
With the caveat that our study protocols only allowed 3
months of observation, we conclude that experimental infection
with H pylori enables vaccine testing in a controlled way.
Clearly, the Ty21a-derived vaccines were not satisfactory.
Ty21a was used because it is a currently available, licensed
human live vaccine and, although strongly attenuated,39 it is
known to trigger mucosa-homing T and B cells.24 25 40 As a
carrier, it induced but also boosted vaccine antigen-specific T
cells expressing mucosa homing receptors, but not in all
volunteers (this study, Bumann et al16 and Metzger et al18)
which was suboptimal. Novel, more potent S typhi carriers
show promise in overcoming this limitation.41 42 The immunisa-
tion schedule may also be varied to improve induction of
mucosa homing T cell responses. We noted a negative
correlation between B cell (ASCs) and T cell responses against
the carrier (rsp =20.4705; p = 0.0153). Official Ty21a vaccina-
tion schedules were adopted here, but these may favour B cell
responses as protection against typhoid fever is positively
correlated with the humoral response. Moreover, prime–boost
regimens combining live and other vaccine formulations may be
more potent, and therapeutic vaccination will also be worth
exploring given the boosting effect noted here.
Importantly, we observed significant reduction of H pylori
burden which was correlated with H pylori-specific T cell
responses. This could have simply reflected passive loss of
infection—‘‘spontaneous clearance’’—but in this case detecting
correlations with two parameters (inflammation pattern and T
cell response in peripheral blood) would not be expected.
However, at present, the possibility that vaccination per se
increased local innate and/or adaptive cross-reactive immune
defence mechanisms leading to reduced H pylori burden cannot
be excluded. In some volunteers, the origin of the T cells was
unclear since they had no sign of active or serological evidence of
past infection. In others, T cells were induced by vaccination.
H pylori-reactive T cells were not exlusively detected in UBT2
volunteers, and it will be important to define markers of a
protective response. In animal studies, despite numerous
attempts,14 markers remain elusive. Results of transcriptome
analyses in vaccinated mice have suggested unexpected mediators
of immunity, adipokines,43 44 but mechanisms are not understood.
Interestingly, factorial analysis of the multidimensional cytome-
try data (not shown) from our T cell analysis suggests that
qualitative differences in T cell responses detectable in PBMCs
may exist between volunteers in UBT+ and UBT2 groups. For
example, CD40L+, IL4+ CD4+ T cells were predominantly
associated with the T cell response in UBT+ volunteers. Thus,
defining predictive markers of protection may become possible.
Regulatory T cells may not be a hurdle for prophylactic
vaccines as they were recruited into the inflamed stomach
mucosa only at later time points, but may close a window of
opportunity for therapeutic vaccination. Inversion of the
challenge infection and vaccination protocol could help to
address this important question in humans.
In summary, this is the first report to show that clearance of H
pylori is correlated with an antigen-specific CD4+ T cell response,
suggesting immunity against this infection in humans.
Figure 4 H pylori-specific CD4+ T cell response is negatively correlated with H pylori infection. Numbers of antigen-specific CD4+ T cells per 56104
CD4+ cells detected after short-term in vitro stimulation of 106 peripheral blood monocytic cells (PBMCs) obtained before (denoted by naive) and
6 weeks after challenge infection (see supplementary table 6 for exact values) of urea breath test (UBT)2 (&) and UBT+ (%) volunteers were plotted
against the overall H pylori score (tables 1 and 2). Stippled lines indicate thresholds (mean of prevaccination values + 3SD = 33 and 32 in the first and
second study, respectively) for significant numbers in specific—that is, cytokine-producing, CD4+ T cells. In the left-hand panel (first study), y-values
represent interferon c (IFNc)+, b7+, CD4+ T cell numbers responding against H pylori urease protein. In the right-hand panel (second study), y-values
indicate b7+, CD40L+, interleukin2 (IL2)+ CD4+ T cell numbers responding to H pylori urease and/or HP0231 representing peptide pools. Fisher exact test
p values that CD4+ T cell responder proportions were not similar in UBT2 and UBT+ groups were: first study p = 0.103, second study p = 0.004,
cumulated, p,0.001).
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